Altimmune's PERFORMA appears on the registry as an 1,800-patient Phase 3

Altimmune's Phase 3 study of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, appeared on the U.S. clinical trials registry with a target enrollment of 1,800 participants and a status of recruiting ^[1]. The trial, called PERFORMA, is designed to test the drug's efficacy, safety and clinical outcomes in patients with the liver disease, and its size puts Altimmune's program in roughly the same range as the incretin-based MASH trials now underway from larger rivals Novo Nordisk and Eli Lilly ^[1].

Pemvidutide is a dual GLP-1/glucagon receptor agonist, meaning it activates two hormone pathways rather than one ^[2]. In earlier company-reported Phase 2 data, it produced average weight loss of about 15.6 percent over 48 weeks, and Altimmune has described its Phase 2b results in MASH as positive ^[2]. The drug has also shown effects beyond weight loss: in the RECLAIM Phase 2 study in alcohol use disorder, reported July 28, 2026, pemvidutide met its primary endpoint and also hit secondary endpoints tied to registration, with 9.1 percent more weight loss than placebo ^[2].

Altimmune's financial position going into this larger trial is described as roughly $535 million in cash as of April 30, 2026, including a $225 million raise completed that same month, against a market capitalization estimated between $440 million and $590 million as of July 2026 ^[2]. Analysts covering the obesity and liver-disease field have flagged this as a company whose fortunes now rest heavily on a single upcoming study: one summary described pemvidutide as "small, speculative, crowded class, binary Phase 3 ahead" ^[2], meaning the trial's outcome could make or break the company's prospects rather than being one data point among many.

The registration itself reflects how much information about drug trials changes quietly on public databases. Services that track the ClinicalTrials.gov registry note that entries are overwritten when details change, with no public record kept of what a listing used to say — so a shift in enrollment size, trial status or projected completion date can happen without notice unless someone is specifically monitoring for it ^[1].

Why it matters for patients

MASH is a form of liver disease tied closely to obesity and metabolic dysfunction, and there is currently no approved GLP-1-class drug specifically for it in the United States. An 1,800-patient trial is large enough to generate the kind of safety and efficacy data regulators typically want before considering approval, but a large trial size alone does not guarantee a positive result. For patients living with or at risk of MASH, this trial represents one more research option under study, not a new treatment available today. People already using GLP-1 medications for diabetes or obesity should know that pemvidutide is a different, unapproved compound made by a different company, so its Phase 2 data on weight loss or liver markers does not carry over to Ozempic, Wegovy, Mounjaro, Zepbound or Foundayo.

The comparison to Novo Nordisk's and Eli Lilly's MASH programs also matters because those companies have far more cash and larger obesity franchises to draw on. Altimmune, by contrast, is running a trial of similar scale with a fraction of the resources, which is part of why analysts describe the outcome as high-stakes for the company ^[2].

What happens next

Altimmune has said its cash is intended to fund the PERFORMA program through a planned 52-week readout, which the company has targeted for 2029 ^[1]. Until then, the trial remains in the recruiting phase, and no efficacy or safety results are available. The sources reviewed here do not provide further detail on interim milestones, patient recruitment progress, or regulatory feedback ahead of that readout, so those details are not yet known.